EUCTR2012-003092-19-IT进行中（未招募）不适用
Reinduction protocol for patients with high-risk neuroblastoma in first relapse - AIEOP NBL REC012
A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA0 个研究点开始时间: 2012年10月19日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Age<18 years -Neuroblastoma diagnosis -First relapse of high risk neuroblastoma -Life Expectancy > 2 months -Performance status : Karnofsky = 60 or Lansky = di 50 -Hematopoietic function: neutrophil > 800/ mm3 and platlet > 75.000 /mm3 -Hepatic and renal function: Creatinin <1.5 normal value (NV) ; Bilirubin total < 1.5 (NV) e AST/ALT < 2.5 NV -Informed Written Consent
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 24
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Concomitant radiotherapy, chemotherapy or immunomodulation. Pregnancy
研究者
相似试验
尚未招募
3 期
Does Escitalopram helps in early recovery and prevent relapse in cases of idiopathic central serous retinopathy which causes blister like elevation at the centre of retina causing loss of visioCTRI/2011/11/002148DrGNageswar Rao110
招募中
2 期
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-BBzeta retroviral vector – A unicenter Phase I/II clinical trial [HD-CAR-1]2024-516832-82-00Universitaetsklinikum Heidelberg AöR63
已完成
不适用
Risk-guided strategy for reducing readmission for Acute Decompensated Heart FailureHeart FailureACTRN12618001273279Baker Institute for Heart and Diabetes122
已完成
不适用
Continuation of Follow-up for Patients who were Previously Enrolled in the Clinical Study: *Open, Prospective Study to Evaluate the Safety and Preliminary Effectiveness of the BaroSense ACE Stapler for the Treatment of Obesity.*1000301810017998ObesityNL-OMON39582Boston Scientific Corporation17
进行中（未招募）
1 期
A clinical study to provide the opportunity to be treated with CTL019, an investigational gene therapy, for children and adolescent patients with a recurrent form of B-cell acute lymphoblastic leukaemia after the closure of the Novartis single-arm phase II pivotal registration trial (Study CCTL019B2202) and to collect additional safety information.Paediatric/young adult patients with B-cell acute lymphoblastic leukaemia who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic SCT.MedDRA version: 19.1 Level: LLT Classification code 10063625 Term: Acute lymphoblastic leukemia recurrent System Organ Class: 100000004864MedDRA version: 19.1 Level: LLT Classification code 10063621 Term: Acute lymphoblastic leukaemia recurrent System Organ Class: 100000004864EUCTR2016-001991-31-ESovartis Farmacéutica, S.A.55